Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients.

Accumulation of wild-type or mutant p53 protein occurs in approximately 50% of human malignancies. This overexpression may generate antigenic epitopes recognized by CTLs. Because normal cells have undetectable levels of p53, these CTLs are likely to be tumor specific. Here, for the first time, we test the hypothesis that full-length wild-type p53 protein can be used for generation of an immune response against tumor cells with p53 overexpression. T cells obtained from nine HLA-A2-positive cancer patients and three HLA-A2-positive healthy individuals were stimulated twice with dendritic cells (DCs) transduced with an adenovirus wild-type p53 (Ad-p53) construct. Significant cytotoxicity was detected against HLA-A2-positive tumor cells with accumulation of mutant or wild-type p53 but not against HLA-A2-positive tumor cells with normal (undetectable) levels of p53 or against HLA-A2-negative tumor cells. This response was specific and mediated by CD8+ CTLs. These CTLs recognized HLA-A2-positive tumor cells expressing normal levels of p53 protein after their transduction with Ad-p53 but not with control adenovirus. Stimulation of T cells with Ad-p53-transduced DCs resulted in generation of CTLs specific for p53-derived peptide. These data demonstrate that DCs transduced with the wild-type p53 gene were able to induce a specific antitumor immune response. This offers a new promising approach to immunotherapy of cancer.

[1]  E. Appella,et al.  A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  J. Gauldie,et al.  Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells. , 1999, Cellular immunology.

[3]  Ishida,et al.  Dendritic cells transduced with wild‐type p53 gene elicit potent anti‐tumour immune responses , 1999, Clinical and experimental immunology.

[4]  H. Hibshoosh,et al.  Wild-type p53 epitope naturally processed and presented by an HLA-B haplotype on human breast carcinoma cells. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  J. Kaplan,et al.  Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. , 1999, Journal of immunology.

[6]  E. Appella,et al.  Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  M. Roth,et al.  Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  M. Westerfield,et al.  Characterization of paired tumor and non‐tumor cell lines established from patients with breast cancer , 1998, International journal of cancer.

[9]  A. Dietz,et al.  High efficiency adenovirus-mediated gene transfer to human dendritic cells. , 1998, Blood.

[10]  S. Chouaib,et al.  Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas. , 1998, Journal of immunology.

[11]  S. Rafii,et al.  Dendritic Cells Genetically Modified with an Adenovirus Vector Encoding the cDNA for a Model Antigen Induce Protective and Therapeutic Antitumor Immunity , 1997, The Journal of experimental medicine.

[12]  F. Graham,et al.  Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination. , 1997, Human gene therapy.

[13]  H. Lyerly,et al.  Generation of dendritic cells in vitro from peripheral blood mononuclear cells with granulocyte-macrophage-colony-stimulating factor, interleukin-4, and tumor necrosis factor-alpha for use in cancer immunotherapy. , 1997, Annals of surgery.

[14]  M. Bevan,et al.  Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. , 1997, Journal of immunology.

[15]  M. Theobald,et al.  Tolerance to p53 by A2.1-restricted Cytotoxic T Lymphocytes , 1997, The Journal of experimental medicine.

[16]  D. Carbone,et al.  Decreased antigen presentation by dendritic cells in patients with breast cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  L. Fugger,et al.  Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[18]  C. Harris,et al.  Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. , 1996, Journal of the National Cancer Institute.

[19]  J. Berzofsky,et al.  Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors. , 1996, Cellular immunology.

[20]  L. Zitvogel,et al.  Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines , 1996, The Journal of experimental medicine.

[21]  A. Levine,et al.  Targeting p53 as a general tumor antigen. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[22]  D. Huhn,et al.  Complete subtyping of the HLA-A locus by sequence-specific amplification followed by direct sequencing or single-strand conformation polymorphism analysis. , 1995, Tissue antigens.

[23]  D J Moss,et al.  Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[24]  S. H. van der Burg,et al.  p53, a potential target for tumor-directed T cells. , 1994, Immunology letters.

[25]  L. Old,et al.  A mouse mutant p53 product recognized by CD4+ and CD8+ T cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[26]  L. Szekely,et al.  Identification of wild‐type and mutant p53 peptides binding to HLA‐A2 assessed by a peptide loading‐deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay , 1994, European journal of immunology.

[27]  M. Lotze,et al.  Flow-cytometric determination of peptide-class I complex formation. Identification of p53 peptides that bind to HLA-A2. , 1994, Human immunology.

[28]  S. H. van der Burg,et al.  In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild‐type p53 , 1993, European journal of immunology.

[29]  Robert Bigelow,et al.  A status report , 1992, Comput. Law Secur. Rev..

[30]  G. Merlo,et al.  Somatic mutations and human breast cancer. A Status Report , 1992, Cancer.

[31]  J. Minna,et al.  High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. , 1992, Oncogene.

[32]  Thierry Soussi,et al.  TP53 tumor suppressor gene: A model for investigating human mutagenesis , 1992, Genes, chromosomes & cancer.

[33]  J. Minna,et al.  Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. , 1990, Oncogene.

[34]  J. Minna,et al.  p53: a frequent target for genetic abnormalities in lung cancer. , 1989, Science.

[35]  M Terada,et al.  Loss of heterozygosity on chromosomes 3, 13, and 17 in small-cell carcinoma and on chromosome 3 in adenocarcinoma of the lung. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[36]  A. Gazdar,et al.  Correspondence re: Martin Brower et al. Growth of Cell Lines and Clinical Specimens of Human Non-Small Cell Lung Cancer in a Serum-free Defined Medium. Cancer Res., 46: 798–806, 1986 , 1986 .

[37]  J. Minna,et al.  Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium. , 1986, Cancer research.

[38]  J. Roth,et al.  Gene therapy for cancer: what have we done and where are we going? , 1997, Journal of the National Cancer Institute.

[39]  C. Newgard,et al.  Use of recombinant adenovirus for metabolic engineering of mammalian cells. , 1994, Methods in cell biology.

[40]  Katsuo Suzuki,et al.  Protein synthesis—dependent cytoplasmic translocation of p53 protein after serum stimulation of growth‐arrested MCF‐7 cells , 1993, Molecular carcinogenesis.

[41]  S. Steinberg,et al.  p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. , 1992, Oncogene.

[42]  R. Steinman,et al.  The dendritic cell system and its role in immunogenicity. , 1991, Annual review of immunology.